PRA was selected to perform a Phase II colorectal cancer trial due to our knowledge from previous colorectal studies as well as our evidence-based approach. In only a few months, our new client experienced PRA’s commitment open communication and engaging relationships and our determination to meet critical deadlines. These qualities are now the foundation of our very successful partnership.
Rare Diseases Newsletter Volume 16, April 2020
Alzheimer's Disease Research 2018
PRA conducted a survey at the 2018 Alzheimer's Association International Conference in Chicago. Across the board we found that the research community…
PRA Revs Up Multiple Myeloma Study
A large biotech company selected PRA to conduct 2 global Phase III open-label studies to measure the safety and efficacy of a multiple myeloma drug.…